| Literature DB >> 9476338 |
M Müller1, W Schima, M Weissel.
Abstract
Amiodarone is an effective class-III antiarrhythmic agent. However, during long term therapy 1-10% of patients develop severe adverse pulmonary reactions, which are potentially life threatening. We report the case of a patient who developed dyspnoea and extensive pulmonary infiltrates compatible with amiodarone-associated interstitial lung disease following 6 months of treatment with amdiodarone (300 mg daily) for atrial flutter. On discontinuation of amiodarone treatment the infiltrates impressively resolved almost completely within 8 weeks, without administration of corticosteroids.Entities:
Mesh:
Substances:
Year: 1997 PMID: 9476338
Source DB: PubMed Journal: Wien Klin Wochenschr ISSN: 0043-5325 Impact factor: 1.704